Syncona: Achilles Announces Sale Of Technology Assets To AstraZeneca - Quick Facts
I'm PortAI, I can summarize articles.
Syncona's investment, Achilles Therapeutics, has sold technology assets to AstraZeneca, including a commercial license for data and samples from the TRACERx non-small cell lung cancer study. AstraZeneca will pay $12 million and become the sponsor of Achilles' Material Acquisition Platform. Achilles plans to reduce its employee headcount and Board size as part of this transition.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: rttnews The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments